Alvimopan

爱维莫潘

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAlvimopan
Drug Alias NameAlvimopanum阿维莫泮爱维莫潘水合物Alvimopan HydrateEntrareg +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor antagonists
TargetsMu opioid receptor
Therapy Area/IndicationsConstipationRectal DiseasesIleus +[10] 
Global Approved IndicationsIleus
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2008/05/20
Country/TerritoryCzechiaCanadaUnited States +[34] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCubist Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalMerck Sharp & Dohme LLCJiangsu Wangao Pharmaceutical Co Ltd +[4] 
Inactive CompaniesCubist Pharmaceuticals LlcUniversity Of California San Diego
Active IndicationsIleusUrinary Bladder Neoplasms
Inactive IndicationsConstipationRectal DiseasesColonic Diseases +[8] 

Other Information

ATC CodeA06AH02
Related LinksWikipediaDrugBankKEGG